DNLI — DENALI THERAPEUTICS INC

Ownership history in Edgestream Partners, L.P.  ·  3 quarters on record

This page tracks every 13F SEC filing in which Edgestream Partners, L.P. reported a position in DENALI THERAPEUTICS INC (DNLI). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.13% (2025 Q2)
Avg. % of fund
0.1%
First filed
2024 Q1
Last filed
2025 Q3
Quarters held
3
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 123,819 -219,104 -63.9% 0.05% $1.8M $14.52
2025 Q2 ADDED 342,923 +230,805 +205.9% 0.13% $4.8M $13.99
2024 Q1 INITIATED 112,118 — — 0.11% $2.3M —
% of Fund (quarterly)    DNLI price (monthly, adj. close)

Other funds also holding DNLI

As of 2025 Q4 — sorted by position size

Crestline Management, LP 3Y 7Y 87.02% Lynx1 Capital Management LP 3Y 5.81% Casdin Capital, LLC 3Y 7Y 1.89% Palo Alto Investors LP 3Y 7Y 1.47% DAFNA Capital Management LLC 3Y 7Y 1.22% STEMPOINT CAPITAL LP 1.19% Monashee Investment Management LLC 3Y 7Y 0.85% Siren, L.L.C. 0.69% MASTERS CAPITAL MANAGEMENT LLC 3Y 7Y 0.67% PSP Research LLC 0.46%
← Back to Edgestream Partners, L.P. Holdings